In honor of World Hemophilia Day on April 17, CSL Behring has donated over 4 million international units of its hemophilia A medications to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) Program, CSL Behring said in a press release.
The GAP Program’s goal is to advance the diagnosis and treatment of bleeding disorders that affect women and girls in emergent nations.
“This year’s theme for World Hemophilia Day is ‘Hear Their Voices,’” Alain Baumann, CEO of World Federation of Hemophilia, said in the release. "There are millions of women and girls around the world living with a bleeding disorder and improving the diagnosis and access to care for the millions of people around the world who have a bleeding disorder and no access to treatment is one of our missions. CSL Behring supports this mission and we are grateful for our longstanding partnership.”
WFH promotes World Hemophilia Day and CSL Behring supports it to boost global awareness of hemophilia and other inherited bleeding disorders, CSL Behring said.
“The GAP Program has helped improve the lives of people who are living with hemophilia around the world by improving treatment access in developing countries,” Jens Oltrogge, head of commercial development coagulation at CSL Behring, said in the release. “This World Hemophilia Day, we are proud to continue to support the GAP Program’s mission. We are also pleased to partner with the bleeding disorders community to increase awareness and diagnosis of all patients living with a bleeding disorder.”